Loading stock data…
ABT
$90.79-0.54 (-0.59%)
Market ClosedLast close Apr 30
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Abbott Laboratories in the Healthcare sector is trading at $90.79. The stock is currently near its 52-week low of $90.29, remaining 24.0% below its 200-day moving average. Technical signals show neutral RSI of 30 and bearish MACD signal, explaining why ABT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 30) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$90.79
Potential Downside
9%
Whystock Fair Value$82.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus25 analysts
Buy
Mean target$118.64+30.7%
Range$92.00 – $143.00
Fundamentals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$159.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.69
Beta
Defensive asset. Lower volatility than the S&P 500.
0.78
Div Yield
Strong income play. Yield provides a meaningful total return floor.
275.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.82%
Volume
Today's trading volume
14.63M
Recent News
Augment makes first move into $8 trillion distribution sector
The AI productivity platform has acquired stealth startup Merlin, a stealth AI company focused on wholesale distribution The post Augment makes first move into $8 trillion distribution sector appeared first on FreightWaves.
Here’s Why Polen Focus Growth Exited Abbott Laboratories (ABT) in Q1
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 was highly volatile for US equities, driven by AI disruption concerns and the US-Israel conflict in Iran and the Middle East. In this backdrop, the Polen […]
How to Pick a Healthcare Stock That Can Weather Any Market
How does a nearly 3% (and growing) dividend yield sound?
HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data
New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large medtech companies.
A Look At Abbott Laboratories ABT Valuation After New Cancerguard Early Cancer Detection Data
Abbott Laboratories (ABT) is back in focus after presenting new multi-biomarker data for its Cancerguard multi cancer early detection test at the 2026 American Association for Cancer Research meeting, alongside recognition for DETECT-A study outcomes. See our latest analysis for Abbott Laboratories. The latest Cancerguard data drop and recent first quarter earnings come against a weaker backdrop, with a 30 day share price return of 13.07% decline and a 1 year total shareholder return of...